Sanjo Akira, Satoi Jujin, Ohnishi Akihiro, Maruno Junko, Fukata Masayuki, Suzuki Naoki
Department of Internal Medicine, Institute of Clinical Medicine and Research, Daisan Hospital, Jikei University School of Medicine, Tokyo, Japan.
J Gastroenterol Hepatol. 2003 Jun;18(6):638-44. doi: 10.1046/j.1440-1746.2003.03026.x.
Thrombocytopenia typically worsens with the progression of liver disease and can become a major clinical complication. Several mechanisms that contribute to thrombocytopenia have been proposed, including hypersplenism accompanied by increased platelet sequestration, platelet destruction mediated by platelet-associated immunoglobulins (PAIgG), and diminished platelet production stimulated by thrombopoietin (TPO). The purpose of the present study was to evaluate the role of each of these mechanisms in patients with liver disease-associated thrombocytopenia.
Twenty-nine patients with liver cirrhosis (LC), 20 of whom were hepatitis C virus (HCV)-seropositive, 29 chronic hepatitis (CH) patients, 24 of whom were HCV-seropositive, and 16 control patients without liver or hematopoetic disease were enrolled in this study. Serum TPO levels, PAIgG, and liver-spleen volumes were determined and correlation analyses were performed.
No differences in serum TPO levels were observed among the three groups. The PAIgG levels were significantly elevated in CH and LC patients (mean +/- SD: 56.5 +/- 42.3 and 144.6 +/- 113.6 ng/107 cells, respectively) compared with the controls (18.9 +/- 2.5 ng/107 cells, P < 0.001 for both). Spleen volume was significantly higher only in LC (428 +/- 239) compared with CH (141 +/- 55) and control (104 +/- 50 cm3) (P < 0.001), while liver volume was not significantly different between the three groups. Correlation analyses demonstrated a significant negative correlation between platelet count with PAIgG (r = - 0.517, P < 0.001) and spleen volume (r = - 0.531, P < 0.001), and no relationship between platelet count and serum TPO level (r = 0.076).
Serum TPO level may not be directly associated with thrombocytopenia in patients with chronic hepatitis and liver cirrhosis. In contrast, spleen volume and PAIgG are associated with thrombocytopenia in such patients, suggesting that hypersplenism and immune-mediated processes are predominant thrombocytopenic mechanisms.
血小板减少症通常会随着肝病的进展而恶化,并可能成为主要的临床并发症。目前已提出了几种导致血小板减少症的机制,包括伴有血小板扣押增加的脾功能亢进、由血小板相关免疫球蛋白(PAIgG)介导的血小板破坏,以及血小板生成素(TPO)刺激的血小板生成减少。本研究的目的是评估这些机制在肝病相关性血小板减少症患者中各自所起的作用。
本研究纳入了29例肝硬化(LC)患者,其中20例丙型肝炎病毒(HCV)血清学阳性;29例慢性肝炎(CH)患者,其中24例HCV血清学阳性;以及16例无肝脏或血液系统疾病的对照患者。测定血清TPO水平、PAIgG以及肝脾体积,并进行相关性分析。
三组之间血清TPO水平未观察到差异。与对照组(18.9±2.5 ng/10⁷细胞)相比,CH和LC患者的PAIgG水平显著升高(均值±标准差:分别为56.5±42.3和144.6±113.6 ng/10⁷细胞,两者P均<0.001)。仅LC患者的脾体积(428±239)显著高于CH患者(141±55)和对照组(104±50 cm³)(P<0.001),而三组之间肝体积无显著差异。相关性分析显示血小板计数与PAIgG(r=-0.517,P<0.001)和脾体积(r=-0.531,P<0.001)之间存在显著负相关,血小板计数与血清TPO水平之间无相关性(r=0.076)。
慢性肝炎和肝硬化患者的血清TPO水平可能与血小板减少症无直接关联。相反,脾体积和PAIgG与这类患者的血小板减少症相关,提示脾功能亢进和免疫介导过程是主要的血小板减少机制。